Thus, combined therapies of anti-TNF-α (or anti-IL-23/IL-17) and anti-IL-22 intervention might be effective in anti-TNF-α (or anti-IL-23/IL-17)-resistant psoriasis individuals. This evidence concerns the gene IL22 and psoriasis.